In a world obsessed with youth, productivity, and endless tomorrows, former Nebraska Senator Ben Sasse has stared into the abyss of a terminal diagnosis and emerged with a message that cuts through the noise: live with ruthless clarity, love your people fiercely, and fight to leave the world better than you found it—even if your time is measured in months, not decades. The New York Times opinion piece “How Ben Sasse Is Living Now That He Is Dying,” published April 9, 2026, captures a raw, hour-long conversation between Sasse and columnist Ross Douthat on the “Interesting Times” podcast. It’s not just a story of suffering; it’s a masterclass in human resilience, faith under fire, and a dying man’s urgent plea to heal the fractured nation he will soon leave behind.
jaxtoday.org
At 54 years old, the father of three, former university president, and eight-year U.S. Senator from Nebraska received the news last December 2025 that he had Stage 4 pancreatic cancer. Doctors delivered what Sasse himself called a “definite death sentence.” The disease had already metastasized aggressively—spreading to his liver, lymph nodes, lungs, vascular system, and manifesting in multiple forms including lymphoma. A full-body scan revealed his torso “chock-full of tumors.” Initial prognosis: three to four months. As of the interview, he was on Day 99 and counting, defying the odds with humor, grit, and an experimental drug that’s both saving and ravaging him. “I’m doing a heck of a lot better than I was doing at Christmas,” he told Douthat, his voice steady despite the visible scars of battle.
Pancreatic cancer is a merciless foe, one of the deadliest cancers known to medicine. According to data from the National Cancer Institute referenced in coverage of Sasse’s case, only about 13.3% of those diagnosed between 2015 and 2021 survived five years. In 2026 alone, an estimated 67,530 Americans will hear the words “pancreatic cancer,” and roughly 52,740 will not survive the year. It hides in shadows—early tumors rarely show on scans, symptoms like back pain (which Sasse first noticed) often get dismissed until the disease has spread. By the time many patients, including Sasse, reach diagnosis, it’s already Stage 4: a “Whac-A-Mole” game with no end, as he memorably described it. The pancreas, tucked behind the stomach, regulates blood sugar and digestion; when its cells mutate wildly, the results are catastrophic. Sasse’s back pain stemmed from tumors pressing against his spine. Doctors initially prescribed 55 milligrams of morphine daily—enough to make him feel “high as a kite” while dulling the agony. Today, he’s down to 30 milligrams, with pain reduced by roughly 80 percent, though nausea still hits in “strong waves” that make him want to “puke.”
Enter daraxonrasib, the experimental oral targeted therapy Sasse is enrolled in through a clinical trial at MD Anderson Cancer Center in Houston. Developed by Revolution Medicines, the drug blocks the mutant proteins driving most pancreatic cancers. Early trial data is promising: about one-third of advanced patients see tumors shrink, many achieve stability, and median survival extends to 13-16 months—double the typical seven to eight months with standard chemotherapy. When combined with chemo, over half see shrinkage and 90% get the disease under control. The FDA granted it fast-track status in October 2025 under a new program designed to accelerate access for deadly diseases like this one. Sasse’s tumors have responded dramatically: torso volume down 76%. His oncologists, Drs. Shubham Pant and Bob Wolff, describe their work as chipping away at a “giant Hoover Dam” with a pickax—small cracks, occasional splashes of progress, but the dam holds for now. Yet the drug is no miracle pill. Sasse calls it a “nasty drug.” It prevents his body from growing new skin, leading to bleeding from places that “shouldn’t be bleeding.” His face and skin feel “nuclear.” Dried blood is visible during the interview. A pharmacist once asked if doctors had done something “electrical” to him. Sasse laughed it off: “Either acid or electric shocks produce a face that looks this hideous.” The side effects are brutal, but they come with the territory of fighting for every extra day.
Beyond the physical toll lies the deeper human story—the one that makes Sasse’s reflections so compelling. He and his wife Melissa, whose epilepsy diagnosis prompted his resignation from the University of Florida presidency in July 2024, share three children: daughters aged 24 and 22, and a 14-year-old son. The “heaviness” of leaving them weighs on him most. He doesn’t want his son growing up without a dad at 16 or his daughters missing their father walking them down the aisle. Yet this same clarity has sharpened his priorities. Sasse has long championed a “not dead yet” philosophy—borrowed from Monty Python and embraced by his family through church visits, nursing home trips, and cemetery outings. Mortality isn’t abstract anymore; it’s a daily companion that forces better choices. “I did immediately feel regrets about a lot of missed prioritization,” he admitted in the podcast. Cancer has become a “prayer of pancreatic cancer,” as he put it—a brutal but clarifying force.
Faith anchors Sasse’s outlook. A committed Christian, he views death not as the end but as a “wicked thief” we should hate with every fiber of our being. “We should call it a wicked thief,” he said. “And yet, it’s pretty good that you pass through the veil of tears one time and then there will be no more tears, there will be no more cancer.” He expects soon to meet the God he’s served. This isn’t blind optimism or denial—it’s a theology forged in fire. Jesus wept at Lazarus’s tomb even knowing resurrection was coming; Sasse echoes that honest grief while clinging to hope. In a culture that often sanitizes or ignores death, his candor is refreshing. He hates the disease, fights it relentlessly with science and medicine, but finds peace in the eternal perspective. Suffering, he believes, can glorify God and redeem time. It’s a perspective that resonates far beyond partisan lines, offering solace to anyone facing their own “Hoover Dam” of hardship.
Sasse’s journey isn’t just personal—it’s political and cultural. The former senator, who represented Nebraska from 2015 to 2023 before leading Midland University and then the University of Florida, has always been a thoughtful conservative voice: institution-builder, education reformer, critic of both parties when they veer into extremes. His books on raising resilient kids and reforming higher education reflect a deep concern for America’s future. Now, facing mortality, he wants to “heal the America he’s leaving behind.” The podcast delves into politics with the clarity only a dying man possesses. He sees a nation riven by division, where tribalism crowds out truth, family, and faith. Cancer has given him the lens to call for renewal: prioritize what matters, reject performative outrage, invest in the next generation. As a Republican who resigned from the Senate amid shifting dynamics and later stepped down from UF for family reasons, Sasse embodies a dying breed of politician—one who values principle over power, service over spectacle. His story challenges all of us, regardless of party, to ask: What legacy are we building? Are we healing or tearing down?
The statistics paint a grim picture, but Sasse’s response injects hope. Pancreatic cancer’s lethality stems from late detection and resistance to treatment, yet advances like daraxonrasib signal progress. Advocacy groups push for more research funding; awareness campaigns urge attention to vague symptoms like unexplained back pain or jaundice. Sasse’s visibility—sharing his “hideous” face and unfiltered struggles—humanizes the disease. It reminds us that behind every statistic is a husband, father, leader whose final chapters are written not in defeat but defiance.
What can we learn from Ben Sasse’s fight? First, mortality clarifies. In our distraction-filled age, few confront death head-on. Sasse’s “not dead yet” mindset turns every day into purposeful action. Second, family is the ultimate priority. His ache at missing milestones underscores what truly lasts: relationships, not résumés. Third, faith and science can coexist. He pursues cutting-edge treatment while anchoring in eternal hope. Fourth, legacy matters. Even with limited time, Sasse urges national healing—better politics, stronger communities, resilient youth. In an era of short attention spans and deep polarization, his voice cuts through like a pickax on that Hoover Dam.
As of this writing in April 2026, Sasse continues his battle. Tumors are shrinking, pain is managed, but the clock ticks. His story isn’t over, but it already teaches volumes. Pancreatic cancer may claim him, as it has so many, yet his example of living fully while dying will endure. He reminds us that death is evil—but it doesn’t get the final word. Through tears, there is light; through suffering, purpose; through one man’s honest reckoning, inspiration for a nation in need of healing.
Sasse’s journey calls us to examine our own lives. If you knew your timeline was finite, how would you reorder your days? Would you mend fences, chase meaning, love harder? His answer is clear: yes. In the shadow of pancreatic cancer’s grim prognosis, Ben Sasse has found light—not by denying the darkness, but by walking through it with faith, family, and a fierce commitment to the America he loves. May his courage inspire us all to live as if every day counts—because it does. And in that shared humanity, perhaps we can begin the healing he so desperately wants to see.
0 Comments